Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults

Abstract

Older adults are at high risk for severe influenza illness, cardiovascular events, hospitalization, functional decline, and death following influenza infection.^1-10 Hospitalization rates for laboratory confirmed influenza are up to 10 times higher in people aged 65 years or older compared with younger adults.¹ An estimated 71% to 90% of deaths from influenza occur in adults aged 65 years or older.^7,8 The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with any US-licensed, age-appropriate, influenza vaccine.¹¹ In the US, influenza vaccines that are licensed for use only in persons aged 65 years and older are trivalent high-dose inactivated influenza vaccine (HD-IIV3 [Fluzone^® High-Dose, licensed 2009]¹²), trivalent adjuvanted inactivated influenza vaccine (aIIV3 [Fluad^®, licensed 2015]¹³), quadrivalent high-dose inactivated influenza vaccine (HD-IIV4 [Fluzone^® High-Dose Quadrivalent, licensed 2019]¹⁴), and quadrivalent inactivated adjuvanted influenza vaccine (aIIV4 [Fluad^® Quadrivalent, licensed 2020]¹⁵).